NCT04002687View on ClinicalTrials.gov

Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

October 29, 2019

Study Completion Date

October 29, 2019

Conditions
Malaria
Interventions
DRUG

ATV-PG 1000-400 mg + AQ 612 mg

The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).

Trial Locations (1)

CR7 7YE

Richmond Pharmacology Ltd., Croydon

All Listed Sponsors
collaborator

Richmond Pharmacology Limited

INDUSTRY

lead

Medicines for Malaria Venture

OTHER

NCT04002687 - Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ) | Biotech Hunter | Biotech Hunter